Predictors of Fatigue in Rheumatoid Arthritis Patients in Remission or in a Low Disease Activity State
- 23 June 2016
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 68 (7) , 1043-1048
Abstract
Objective: Fatigue is a frequently occurring symptom in patients with rheumatoid arthritis (RA). Our aims were to assess the level of reported fatigue in RA patients who had achieved remission or low disease activity after 6 months of treatment with disease‐modifying antirheumatic drugs (DMARDs), and to explore associations between fatigue and demographics, disease activity, and other patient‐reported outcomes in this patient group.Methods: A total of 2,193 RA patients (ages ≥18 years) starting either methotrexate (MTX) monotherapy or a tumor necrosis factor inhibitor in combination with MTX were retrieved from the Norwegian Disease‐Modifying Antirheumatic Drugs Register (NOR‐DMARD). At the 6‐month followup, 699 patients (31.9%) were in remission or in a low disease activity state. Bivariate and multivariate linear regression analyses were conducted, with the fatigue visual analog scale (VAS) at 6 months as the dependent variable. Age, sex, disease duration, treatment group, erythrocyte sedimentation rate (ESR), the swollen and tender joint count in 28 joints, the pain VAS score, and disability at baseline and at 6 months were tested as predictors of fatigue at 6 months.Results: At 6 months, the median (25th, 75th percentile) level of fatigue was 20.0 mm (6.0, 43.0), and a fatigue VAS score of ≥40 mm was reported by 27.9% of patients. In the multivariate analysis, lower ESR and higher pain at baseline were statistically significant predictors of higher levels of fatigue (P < 0.001). In the multivariate cross‐sectional analysis at 6 months, younger age and greater pain were significantly associated with higher levels of fatigue (P < 0.001).Conclusion: Pain levels at baseline and at 6 months were associated with a higher level of fatigue. Patients in remission or in a low disease activity state may need nonpharmacologic interventions to manage their pain and fatigue.Keywords
This publication has 14 references indexed in Scilit:
- Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisRheumatology, 2014
- Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD studyAnnals of the Rheumatic Diseases, 2014
- Fatigue and Factors Related to Fatigue in Rheumatoid Arthritis: A Systematic ReviewArthritis Care & Research, 2013
- The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patientsScandinavian Journal of Rheumatology, 2012
- Fatigue in rheumatoid arthritis: time for a conceptual modelRheumatology, 2010
- Physical and psychosocial correlates of severe fatigue in rheumatoid arthritisRheumatology, 2010
- Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendationsArthritis Care & Research, 2008
- Predictors of fatigue over 1 year among people with rheumatoid arthritisPsychology, Health & Medicine, 2008
- Patients' perceptions of fatigue in rheumatoid arthritis: Overwhelming, uncontrollable, ignoredArthritis Care & Research, 2005
- Validation of rheumatoid arthritis improvement criteria that include simplified joint countsArthritis & Rheumatism, 1998